Premium
Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes
Author(s) -
Desch S.,
Sonnabend M.,
Niebauer J.,
Sixt S.,
Sareban M.,
Eitel I.,
De Waha S.,
Thiele H.,
Blüher M.,
Schuler G.
Publication year - 2010
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2010.01234.x
Subject(s) - prediabetes , rosiglitazone , medicine , coronary artery disease , cardiology , disease , diabetes mellitus , type 2 diabetes , endocrinology , receptor
We conducted a three‐arm, parallel‐group, randomized, controlled trial to compare the effects of rosiglitazone and physical exercise on endothelial function in patients with coronary artery disease and impaired fasting glucose or impaired glucose tolerance over a 6‐month period. Group A received rosiglitazone tablets 8 mg daily (n = 16), group B underwent a structured physical exercise programme (n = 15) and group C served as a control group (n = 12). At baseline and after 6 months, brachial artery ultrasound imaging was performed to assess reactive flow‐mediated dilation (FMD). Rosiglitazone treatment and exercise both led to significant improvements in insulin resistance at 6 months, whereas no change was observed in control patients. FMD improved significantly in physical exercise patients, whereas no change could be observed in patients receiving rosiglitazone or in the control group. Between‐group comparisons also showed a significant relative improvement in FMD in exercise patients compared with rosiglitazone.